Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy

by Schopper, Heather, Bontumasi, Nicholas M., Milhem, Mohammed, Wanat, Karolyn A.
Published 2016

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases

by Phadke, Sneha D., Ghabour, Ramez, Swick, Brian L., Swenson, Andrea, Milhem, Mohammed, Zakharia, Yousef
Published 2016

Pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab treatment for metastatic melanoma

by Mutgi, Krishna A.J., Milhem, Mohammed, Swick, Brian L., Liu, Vincent
Published 2016

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

by Xia, Chang, Leon-Ferre, Roberto, Laux, Douglas, Deutsch, Jeremy, Smith, Brian J., Frees, Melanie, Milhem, Mohammed
Published 2014

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously u...

by Puzanov, Igor, Milhem, Mohammed, Andtbacka, Robert, Minor, David, Hamid, Omid, Li, Ai, VanderWalde, Ari, Kaufman, Howard
Published 2013

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proc...

by Patel, Sapna, Milhem, Mohammed, Hallmeyer, Sigrun, Daniels, Gregory, Cranmer, Lee, Taback, Bret, Flaherty, Lawrence, Aung, Sandra, Lowder, James, Sharfman, William
Published 2014

TAZ and YAP are frequently activated oncoproteins in sarcomas

by Fullenkamp, Colleen A., Hall, Sarah L., Jaber, Omar I., Pakalniskis, Brittany L., Savage, Erica C., Savage, Johanna M., Ofori-Amanfo, Georgina K., Lambertz, Allyn M., Ivins, Stephanie D., Stipp, Christopher S., Miller, Benjamin J., Milhem, Mohammed M., Tanas, Munir R.
Published 2016

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

by Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Published 2016

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unres...

by Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Published 2016

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melan...

by Andtbacka, Robert HI, Collichio, Frances A, Amatruda, Thomas, Senzer, Neil, Chesney, Jason, Delman, Keith, Spitler, Lynn, Puzanov, Igor, Agarwala, Sanjiv, Milhem, Mohammed, Harrington, Kevin, Middleton, Mark, Li, Ai, Shilkrut, Mark, Coffin, Robert, Kaufman, Howard
Published 2014

A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01...

by Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Published 2014